Longeveron Taps Biotech CFO Veteran Jhaveri Ahead of Key Trial Results
Event summary
- Nirav Jhaveri appointed CFO of Longeveron, succeeding Marie Washburn who returns to her role as Corporate Controller.
- Jhaveri brings 25 years of capital markets and biotech experience, including CFO roles at Opus Genetics, Insilico Medicine, and Journey Medical.
- Longeveron's Phase 2b clinical trial for HLHS (hypoplastic left heart syndrome) expected to report top-line results in September 2026.
- Laromestrocel (Lomecel-B®) is Longeveron's lead stem cell therapy targeting four indications, including HLHS and Alzheimer’s disease.
The big picture
Longeveron’s appointment of Nirav Jhaveri as CFO underscores its focus on capital efficiency and strategic financing ahead of critical trial data. The move comes as the biotech sector faces heightened scrutiny on clinical validation and operational scalability, particularly for regenerative medicine therapies. Jhaveri’s track record in biotech M&A and IPO readiness could position Longeveron for potential partnerships or licensing deals as it navigates its asset-light operating model.
What we're watching
- Trial Outcomes
- Whether the Phase 2b trial results for HLHS in September 2026 will validate laromestrocel’s efficacy and accelerate regulatory approval.
- Financial Strategy
- How Jhaveri’s capital markets expertise will shape Longeveron’s funding strategy amid clinical-stage biotech financing challenges.
- Pipeline Expansion
- The pace at which Longeveron advances laromestrocel across its four indications, particularly in Alzheimer’s disease and pediatric dilated cardiomyopathy.
Related topics